. Author manuscript; available in PMC: 2016 Mar 15.

Published in final edited form as: Clin Cancer Res. 2015 Jan 8;21(6):1395–1405. doi: 10.1158/1078-0432.CCR-14-2300

Table 1. In vivo activity of RG7112 against MLL-ALL xenografts.

Xenograft	Median EFS (Days)		LGD (Days)	Log-rank P-value (treated versus control)	Median ORM

	Control	RG7112
MLL-2	9.7	41.4	31.7	0.0002	CR
MLL-3	10.5	32.2	21.7	<0.0001	CR
MLL-5	6.4	23.5	17.1	<0.0001	CR
MLL-6	4.7	34.8	30.1	<0.0001	CR
MLL-7^a	6.8	51.5	44.7	<0.0001	MCR
MLL-8	6.8	26.6	26.6	0.0011	CR
MLL-14	6.3	27.3	27.3	<0.0001	CR

Values in bold signify statistically significant drug effects (P<0.05).

Data for this xenograft previously published (31).